TR200000792T2 - Vitronektin reseptör antagonistleri. - Google Patents

Vitronektin reseptör antagonistleri.

Info

Publication number
TR200000792T2
TR200000792T2 TR2000/00792T TR200000792T TR200000792T2 TR 200000792 T2 TR200000792 T2 TR 200000792T2 TR 2000/00792 T TR2000/00792 T TR 2000/00792T TR 200000792 T TR200000792 T TR 200000792T TR 200000792 T2 TR200000792 T2 TR 200000792T2
Authority
TR
Turkey
Prior art keywords
vitronectin receptor
receptor antagonists
vitronectin
osteoporosis
compound
Prior art date
Application number
TR2000/00792T
Other languages
English (en)
Inventor
H. Miller William
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Publication of TR200000792T2 publication Critical patent/TR200000792T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Bu bulus, bir vitronektin reseptör antagonisti olup osteoporozun tedavisinde faydali olan bir (formul (I)) bilesigi ya da onun farmasötik olarak kabul edilebilir bir tuzu ile ilgilidir.
TR2000/00792T 1997-09-24 1998-09-24 Vitronektin reseptör antagonistleri. TR200000792T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5983297P 1997-09-24 1997-09-24

Publications (1)

Publication Number Publication Date
TR200000792T2 true TR200000792T2 (tr) 2000-09-21

Family

ID=22025570

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/00792T TR200000792T2 (tr) 1997-09-24 1998-09-24 Vitronektin reseptör antagonistleri.

Country Status (13)

Country Link
EP (1) EP1017387A4 (tr)
JP (1) JP2002528380A (tr)
KR (1) KR20010024247A (tr)
CN (1) CN1273529A (tr)
AU (1) AU9577498A (tr)
BR (1) BR9813208A (tr)
CA (1) CA2303846A1 (tr)
HU (1) HUP0003949A2 (tr)
IL (1) IL135189A0 (tr)
NO (1) NO20001514L (tr)
PL (1) PL339413A1 (tr)
TR (1) TR200000792T2 (tr)
WO (1) WO1999015170A1 (tr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1150965A4 (en) 1999-02-03 2002-05-15 Merck & Co Inc BENZAZEPINE DERIVATIVES AS ALPHA-V INTGRIN RECEPTOR ANTAGONISTS
US6514964B1 (en) * 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
AU2001288485A1 (en) * 2000-08-29 2002-03-13 Balekudru Devadas Compounds containing a bicyclic ring system useful as alpha v beta 3 antagonists
US6531494B1 (en) 2001-08-29 2003-03-11 Pharmacia Corporation Gem-substituted αvβ3 antagonists
PL365729A1 (en) * 2000-08-30 2005-01-10 Pharmacia Corporation Gem-substituted alpha v beta 3 integrin antagonists
ES2366775T3 (es) 2001-04-24 2011-10-25 Merck Patent Gmbh POLITERAPIA UTILIZANDO AGENTES ANTIANGIOGÉNICOS Y TNF(alfa).
WO2003059251A2 (en) 2001-10-22 2003-07-24 The Scripps Research Institute Antibody targeting compounds
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
AU2007207465B2 (en) 2006-01-18 2012-12-06 Merck Patent Gmbh Specific therapy using integrin ligands for treating cancer
BRPI0806596A2 (pt) 2007-01-18 2013-07-23 Merck Patent Ges Mit Berchraenkter Haftung medicamento e terapia especÍfica usando-se ligantes de integrina para o tratamento de cÂncer
AU2008321770B2 (en) * 2007-11-16 2012-09-06 Ube Industries, Ltd. Benzazepinone compound
US8076475B2 (en) * 2008-03-06 2011-12-13 Glaxosmithkline Llc Process
WO2010093706A2 (en) 2009-02-10 2010-08-19 The Scripps Research Institute Chemically programmed vaccination
WO2010113958A1 (ja) 2009-03-30 2010-10-07 宇部興産株式会社 眼の疾患の治療又は予防のための医薬組成物
JP5572996B2 (ja) * 2009-05-15 2014-08-20 宇部興産株式会社 ベンズアゼピノン化合物を有効成分として含有する医薬
EP2445534A2 (en) 2009-05-25 2012-05-02 Merck Patent GmbH Continuous administration of cilengitide in cancer treatments
CN103864765B (zh) * 2014-03-05 2016-02-10 天津药物研究院 含有五元杂环的苯并氮杂卓类衍生物、其制备方法和用途
ES2864079T3 (es) 2014-05-30 2021-10-13 Pfizer Derivados de carbonitrilo como moduladores selectivos del receptor de andrógenos
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA955391B (en) * 1994-06-29 1996-02-09 Smithkline Beecham Corp Vitronectin receptor antagonists
UA60311C2 (uk) * 1996-10-02 2003-10-15 Смітклайн Бічам Корпорейшн Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція
EP0946180A4 (en) * 1996-10-07 2003-07-23 Smithkline Beecham Corp METHODS FOR STIMULATING BONE FORMATION

Also Published As

Publication number Publication date
KR20010024247A (ko) 2001-03-26
NO20001514D0 (no) 2000-03-23
BR9813208A (pt) 2000-08-22
PL339413A1 (en) 2000-12-18
IL135189A0 (en) 2001-05-20
CN1273529A (zh) 2000-11-15
NO20001514L (no) 2000-03-23
CA2303846A1 (en) 1999-04-01
WO1999015170A1 (en) 1999-04-01
EP1017387A1 (en) 2000-07-12
EP1017387A4 (en) 2004-08-18
HUP0003949A2 (hu) 2001-10-28
JP2002528380A (ja) 2002-09-03
AU9577498A (en) 1999-04-12

Similar Documents

Publication Publication Date Title
ATE372768T1 (de) N-(2-arylethyl) benzylamine als 5-ht6 rezeptor- antagoniste
TR199801253T2 (tr) Vitronektin reseptörü antagonistleri.
TR200201506T2 (tr) Terapötik maddeler olarak kinaz inhibitörleri
BR0206595A (pt) Composto, composição farmacêutica, e uso de um composto
TR200000786T2 (tr) Vitronektin reseptör antagonisti
TR199801255T2 (tr) Vitronektin reseptör antagonistleri.
BG66085B1 (bg) Фенилаланинови производни
BR9811844A (pt) 4-aminopirrol[3,2-d]pirimidinas como receptor antagonista do neuropeptìdeo y
CY1110243T1 (el) Ανταγωνιστες npyy5
TR200101398T2 (tr) Pirolidin türevleri-CCR-3 reseptörü antagonistleri.
DK1173433T3 (da) Cyanopyrroler som progesteronreceptoragonister
TR200605471T2 (tr) AT-1 veya AT-2 reseptörlerindeki artışın neden olduğu hastalıkların tedavisi için at-1 reseptör antagonisti veya at-2 reseptör modülatörünün kullanımı@
TR199801594A2 (tr) CCR-3 reseptör antagonistleri.
TR200102489T2 (tr) 3-Fenilpiridin Türevleri ve bunların NK-1 alıcı antagonistler olarak kullanılması
TR199901575T2 (tr) Vitronektin reseptör antagonistleri.
BR0015963A (pt) Compostos de uréia antagonistas receptor muscarìnico, composições farmacêuticas compreendendo tais compostos e método de preparação destes compostos
TR199901710T2 (tr) IL-8 reseptör antagonistleri.
BR0010215A (pt) Derivados de indolina como antagonistas de progesterona
AU4926301A (en) Lpa receptor agonists and antagonists and methods of use
CY1108054T1 (el) Θεραπεια της δυσκινησιας μεσω ανταγωνιστων επιλεκτικων οπιουχων mu
NO20001514L (no) Vitronectin-reseptor-antagonist
TR199701645A2 (tr) Vitronektin reseptör antagonistleri,bunlarin imalati ve kullanimi
SE9702651D0 (sv) Novel compounds
TR200101654T2 (tr) Vitronektin resept”r antagonistleri
BR9809848A (pt) Composição